Verity Pharma News

Toronto, Ontario, March 7, 2018 — Verity Pharmaceuticals Inc. is pleased to announce a manufacturing and supply agreement with Bi-Coastal Pharma International of Shrewsbury, New Jersey for the production of Phenazopyridine Hydrochloride Tablets in 100mg and 200mg strengths.

Under the terms of the agreement, Bi-Coastal will supply the finished packaged product to Verity who will handle marketing and distribution. Phenazopyridine is a urinary tract analgesic with a long history of use in Canada and the US. Brought to market in the 1970’s, supply of the drug was discontinued in Canada in 2009, much to the disappointment of physicians and their patients.

“After a nine year absence in Canada, we are pleased to facilitate the reintroduction of a high quality cGMP manufactured product, once again providing physicians with a safe and satisfactory treatment for urinary tract pain and discomfort. We will continue to focus on efforts like this that fulfill unmet medical needs within the Canadian healthcare community” – Howard Glase, CEO Verity Pharma

Typically prescribed for pain caused by Urinary Tract Infections (UTIs), phenazopyridine can also be used to treat patients suffering from pain caused by Interstitial Cystitis (IC), Chronic pelvic pain syndrome (CPPS), prostatitis, post surgical and catheterization irritations. “For the past decade patients have had to resort to either travelling to the U.S. to get phenazopyridine, or simply biting the bullet and doing without. Physicians (and their patients!) will be quite relieved to know that this unique agent is once again available in Canada.” – Dr. Neil Fleshner MD, MPH, FRCSC, Chairman of Urology at University of Toronto, Chief Medical Officer, Verity Scientific Advisory Board

Bi-Coastal Pharma International LLC is a privately-owned New Jersey based pharmaceutical marketing company able to source API, manufacture and label generic pharmaceutical products across a wide range of therapeutic areas in various dosage forms. Bi-Coastal offers prescription tablets, capsules, and topical dose form generic products that are sold through all major distribution channels in the United States including national and regional wholesalers, distributors, chain drug stores, mass merchandisers, GPO’s, managed care organizations and state and government facilities. “Bi-Coastal’s primary focus is to continually provide the highest levels of quality and service in the products we offer the pharmaceutical trade. We value our industry relationships and are excited to be working together with Verity Pharma to help bring phenazopyridine back to Canadian physicians and their patients.” – Ralph Massa, Jr.- President and CEO, Bi-Coastal Pharma International

Verity Pharma is a specialty pharmaceutical company focused on providing therapeutically relevant legacy agents to the Canadian health care community. Our mission is to provide access to prescription products that are in short supply, have not yet been made available or suppliers have withdrawn from the market in Canada. Phenazopyridine is just one of several important products on track for launch in 2018 and 2019.